Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 112

1.

Thrombospondin1 (TSP1) replacement prevents cerebral cavernous malformations.

Lopez-Ramirez MA, Fonseca G, Zeineddine HA, Girard R, Moore T, Pham A, Cao Y, Shenkar R, de Kreuk BJ, Lagarrigue F, Lawler J, Glass CK, Awad IA, Ginsberg MH.

J Exp Med. 2017 Nov 6;214(11):3331-3346. doi: 10.1084/jem.20171178. Epub 2017 Sep 28.

PMID:
28970240
2.

Src- and Fyn-dependent apical membrane trafficking events control endothelial lumen formation during vascular tube morphogenesis.

Kim DJ, Norden PR, Salvador J, Barry DM, Bowers SLK, Cleaver O, Davis GE.

PLoS One. 2017 Sep 14;12(9):e0184461. doi: 10.1371/journal.pone.0184461. eCollection 2017.

3.

Plasma Biomarkers of Inflammation Reflect Seizures and Hemorrhagic Activity of Cerebral Cavernous Malformations.

Girard R, Zeineddine HA, Fam MD, Mayampurath A, Cao Y, Shi C, Shenkar R, Polster SP, Jesselson M, Duggan R, Mikati AG, Christoforidis G, Andrade J, Whitehead KJ, Li DY, Awad IA.

Transl Stroke Res. 2018 Feb;9(1):34-43. doi: 10.1007/s12975-017-0561-3. Epub 2017 Aug 17.

PMID:
28819935
4.

Tumor necrosis factor-α levels and non-surgical bleeding in continuous-flow left ventricular assist devices.

Tabit CE, Coplan MJ, Chen P, Jeevanandam V, Uriel N, Liao JK.

J Heart Lung Transplant. 2018 Jan;37(1):107-115. doi: 10.1016/j.healun.2017.06.001. Epub 2017 Jun 8.

5.

Combined HMG-COA reductase and prenylation inhibition in treatment of CCM.

Nishimura S, Mishra-Gorur K, Park J, Surovtseva YV, Sebti SM, Levchenko A, Louvi A, Gunel M.

Proc Natl Acad Sci U S A. 2017 May 23;114(21):5503-5508. doi: 10.1073/pnas.1702942114. Epub 2017 May 12.

6.

Nuclear Localization of Integrin Cytoplasmic Domain-associated Protein-1 (ICAP1) Influences β1 Integrin Activation and Recruits Krev/Interaction Trapped-1 (KRIT1) to the Nucleus.

Draheim KM, Huet-Calderwood C, Simon B, Calderwood DA.

J Biol Chem. 2017 Feb 3;292(5):1884-1898. doi: 10.1074/jbc.M116.762393. Epub 2016 Dec 21.

PMID:
28003363
7.

Cerebral Cavernous Malformations: Review of the Genetic and Protein-Protein Interactions Resulting in Disease Pathogenesis.

Baranoski JF, Kalani MY, Przybylowski CJ, Zabramski JM.

Front Surg. 2016 Nov 14;3:60. eCollection 2016. Review. Erratum in: Front Surg. 2017 Jul 18;4:31.

8.

RhoA Kinase Inhibition With Fasudil Versus Simvastatin in Murine Models of Cerebral Cavernous Malformations.

Shenkar R, Shi C, Austin C, Moore T, Lightle R, Cao Y, Zhang L, Wu M, Zeineddine HA, Girard R, McDonald DA, Rorrer A, Gallione C, Pytel P, Liao JK, Marchuk DA, Awad IA.

Stroke. 2017 Jan;48(1):187-194. doi: 10.1161/STROKEAHA.116.015013. Epub 2016 Nov 22.

9.

The pathobiology of vascular malformations: insights from human and model organism genetics.

Wetzel-Strong SE, Detter MR, Marchuk DA.

J Pathol. 2017 Jan;241(2):281-293. doi: 10.1002/path.4844. Epub 2016 Dec 4. Review.

10.

RHO binding to FAM65A regulates Golgi reorientation during cell migration.

Mardakheh FK, Self A, Marshall CJ.

J Cell Sci. 2016 Dec 15;129(24):4466-4479. Epub 2016 Nov 2.

11.

Oxidative stress and inflammation in cerebral cavernous malformation disease pathogenesis: Two sides of the same coin.

Retta SF, Glading AJ.

Int J Biochem Cell Biol. 2016 Dec;81(Pt B):254-270. doi: 10.1016/j.biocel.2016.09.011. Epub 2016 Sep 14.

12.

Endothelial exocytosis of angiopoietin-2 resulting from CCM3 deficiency contributes to cerebral cavernous malformation.

Jenny Zhou H, Qin L, Zhang H, Tang W, Ji W, He Y, Liang X, Wang Z, Yuan Q, Vortmeyer A, Toomre D, Fuh G, Yan M, Kluger MS, Wu D, Min W.

Nat Med. 2016 Sep;22(9):1033-1042. doi: 10.1038/nm.4169. Epub 2016 Aug 22.

13.

Micro-CT Imaging Reveals Mekk3 Heterozygosity Prevents Cerebral Cavernous Malformations in Ccm2-Deficient Mice.

Choi JP, Foley M, Zhou Z, Wong WY, Gokoolparsadh N, Arthur JS, Li DY, Zheng X.

PLoS One. 2016 Aug 11;11(8):e0160833. doi: 10.1371/journal.pone.0160833. eCollection 2016.

14.

Micro-computed tomography in murine models of cerebral cavernous malformations as a paradigm for brain disease.

Girard R, Zeineddine HA, Orsbon C, Tan H, Moore T, Hobson N, Shenkar R, Lightle R, Shi C, Fam MD, Cao Y, Shen L, Neander AI, Rorrer A, Gallione C, Tang AT, Kahn ML, Marchuk DA, Luo ZX, Awad IA.

J Neurosci Methods. 2016 Sep 15;271:14-24. doi: 10.1016/j.jneumeth.2016.06.021. Epub 2016 Jun 23.

15.

Time to make the doughnuts: Building and shaping seamless tubes.

Sundaram MV, Cohen JD.

Semin Cell Dev Biol. 2017 Jul;67:123-131. doi: 10.1016/j.semcdb.2016.05.006. Epub 2016 May 10. Review.

PMID:
27178486
16.

Beyond multiple mechanisms and a unique drug: Defective autophagy as pivotal player in cerebral cavernous malformation pathogenesis and implications for targeted therapies.

Marchi S, Trapani E, Corricelli M, Goitre L, Pinton P, Retta SF.

Rare Dis. 2016 Jan 25;4(1):e1142640. doi: 10.1080/21675511.2016.1142640. eCollection 2016.

17.

Cerebral cavernous malformations arise from endothelial gain of MEKK3-KLF2/4 signalling.

Zhou Z, Tang AT, Wong WY, Bamezai S, Goddard LM, Shenkar R, Zhou S, Yang J, Wright AC, Foley M, Arthur JS, Whitehead KJ, Awad IA, Li DY, Zheng X, Kahn ML.

Nature. 2016 Apr 7;532(7597):122-6. doi: 10.1038/nature17178. Epub 2016 Mar 30. Erratum in: Nature. 2016 May 25;536(7617):488.

18.
19.
20.

Cytochrome P450 and matrix metalloproteinase genetic modifiers of disease severity in Cerebral Cavernous Malformation type 1.

Choquet H, Trapani E, Goitre L, Trabalzini L, Akers A, Fontanella M, Hart BL, Morrison LA, Pawlikowska L, Kim H, Retta SF.

Free Radic Biol Med. 2016 Mar;92:100-9. doi: 10.1016/j.freeradbiomed.2016.01.008. Epub 2016 Jan 19.

Supplemental Content

Support Center